

Synthesis of 3-indolylazoles and meridianin derivatives from indolyl enamionitriles

Ana M. F. Oliveira-Campos^{*a}, Abdellatif M. Salaheldin^a, Filipe A. Almeida Paz^b, and Ligia M. Rodrigues^a

^a*Centro de Química, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal*
amcampos@quimica.uminho.pt

^b*Department of Chemistry, CICECO, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal*

Abstract

The reaction of indole derivatives with cyanoacetic acid followed by treatment with DMFDMA gave the intermediate indolyl enamionitriles (**3**). Further reaction with aminoguanidine yielded 5'-cyanomeridianin analogues (**4**). The same intermediate reacted with *p*-methoxyphenylhydrazine to give the pyrazolyl derivative (**8**).

Treatment of (2*E*)-3-dimethylamino-2-(1*H*-indol-3-yl)-propenoate (**3a**) with hydroxylamine hydrochloride in basic medium afforded (5-amino-isoxazol-4-yl)-(1*H*-indol-3-yl)-methanone (**5**) and the acrylic acid derivative (**6**) after a short or a long heating, respectively. Unequivocal structural elucidation of the latter compound was achieved from single-crystal X-ray diffraction studies.

Keywords: Indole, Alkaloids, Enaminonitrile, Meridianins, 3-Indolylazoles

Introduction

Enaminonitriles are versatile reagents which have been efficiently utilized for the synthesis of heteroaromatics.¹ Meridianin alkaloids, isolated from the south atlantic tunicate *Aplidium meridianum*,² are indole derivatives substituted at the C-3 position by a 2-aminopyrimidine ring.

Since abnormal protein phosphorylation is related to many human diseases interest on the search for inhibitors of kinases has increased. A vast number of inhibitors of CDKs have been discovered, however, only very few GSK-3 inhibitors have been described.

Meridianins²⁻⁴ (Fig. 1) were described as potent kinase inhibitors,⁴ inhibiting CDKs, GSK-3, PKA and other protein kinases in the low micromolar range. Some derivatives displayed also antitumor activity.⁵

There are three reported approaches for the synthesis of meridianins from indole derivatives based on a Suzuki cross-coupling with indole-3-boronic acid derivatives.⁶ A Bredereck synthesis was also described from β -enaminones, which were, in turn, obtained from 3-acetylindole derivatives.^{5,7,8} More recently, meridianins were also obtained from trimethylsilylindole derivatives.⁹





Figure 1. General representation of meridianin alkaloids.

Results and discussion

Following our interest in the chemistry of β -enaminonitriles,¹⁰⁻¹³ in this manuscript we describe our most recent results that explore the potential of 3(2*E*)-3-dimethylamino-2-(1*H*-indol-3-yl)-propenoate in the synthesis of 5'-cyanomeridianin C, G and 3-heteroarylindoles. Commercially available indole and indole-3-carboxaldehyde were employed as the starting materials giving access to the meridianin analogs **4a-c** in a straightforward three-step synthesis following the Brederick approach⁷ (Scheme 1), and to **14** from one-pot synthesis as shown in Scheme 3.



Scheme 1

Recently, a facile procedure for the cyanoacetylation of indoles leading to compounds **2a-c** has been reported.¹⁴ This one-step approach, applying cyanoacetic acid for the inclusion of the cyanoacetyl functionality, provides an easy access to cyanoacetylated indoles

2a-c. The Brederick protocol⁷ was used for the formation of the 2-aminopyrimidine ring. When compounds **2a-c** were treated with dimethylformamide dimethylacetal (DMFDMA),¹⁵ without solvent at room temperature, the corresponding enaminonitriles **3a-c** were obtained in yields ranging from 78 to 88%.

Direct conversion of **3a-c** into 5'-cyano meridianin C and meridianin G derivatives **4a-c**, involving the formation of the 2-aminopyrimidine ring, was achieved in 70-78% by treatment with guanidine hydrochloride in the presence of anhydrous potassium carbonate (Scheme 1). The structure of compounds **4a-c** was established on the basis of elemental analysis, IR, mass, ¹H and ¹³C NMR spectral data studies (*cf.* Experimental Section).

Heating compound **3a** for 7 hours, with hydroxylamine hydrochloride in the presence of base, did not produce the isoxazole **5**, but led instead to the formation of the indole derivative **6**.

The alternative structure **5** was excluded based on FT-IR and NMR data. The ¹H NMR spectrum of **6** showed two signals that are D₂O exchangeable at 7.90 and 12.20 and a singlet for H-2 at 8.48 ppm, while ¹³C NMR showed a carbonyl signal at 181.55 ppm (C-3). Unequivocal structural elucidation was achieved from single-crystal X-ray diffraction studies. Compound **6** crystallises in the centrosymmetric monoclinic *C2/c* space group, with the asymmetric unit being composed of a whole molecular unit (Figure 2) with typical geometrical features for the bond lengths and angles (see caption of Figure 2).




Figure 2. Schematic representation of the molecular unit of compound **6**. Non-hydrogen atoms are represented as thermal ellipsoids (drawn at the 50% probability level) and hydrogen atoms as small spheres with arbitrary radii. The atomic labelling scheme is also provided for all non-hydrogen atoms. Selected bond lengths (in Å): O1–C1 1.262(2); O2–C1 1.337(3); O3–C4 1.316(2); N1–C3 1.140(2); N2–C5 1.349(2); N2–C8 1.373(2); C1–C2 1.459(2); C2–C4 1.392(3); C2–C3 1.417(2); C4–C6 1.442(2); C5–C6 1.387(2); C6–C7 1.446(2); C7–C12 1.406(2); C7–C8 1.413(2); C8–C9 1.392(3); C9–C10 1.371(3); C10–C11 1.411(3); C11–C12 1.364(3). Selected bond angles (in degrees): C5–N2–C8 109.70(15); O1–C1–O2 120.18(16); O1–C1–C2 120.15(17); O2–C1–C2 119.66(16); C4–C2–C3 122.47(15); C4–C2–C1 120.52(15); C3–C2–C1 116.99(16); N1–C3–C2 176.64(19); O3–C4–C2 119.06(16); O3–C4–C6 113.99(16); C2–C4–C6 126.95(15); N2–C5–C6 110.16(17); C5–C6–C4 128.31(17); C5–C6–C7 105.91(15); C4–C6–C7 125.78(15); C12–C7–C8 118.12(17); C12–C7–C6 135.45(16); C8–C7–C6 106.43(15); N2–C8–C9 129.18(17); N2–C8–C7 107.79(16); C9–C8–C7 123.03(17); C10–C9–C8 117.23(18); C9–C10–C11 120.8(2); C12–C11–C10 121.9(2); C11–C12–C7 118.86(18).

When the reaction proceeded under mild heating conditions, for 30 minutes at 60°C, the product isolated (26%) was the oxazole derivative **5**. The singlet due to H-3 may be seen at 8.97 and the NH₂ signal is located at 8.18 ppm and readily exchanges with D₂O. It is assumed that **5** may be formed initially and with prolonged heating, in basic medium, yields **6**. Removal of the proton 3 from **5**, which is known to happen in basic medium, would open the isoxazole ring to an amide whose hydrolysis would give the corresponding carboxylic acid derivative (**6**). Ring opening always occurs in the same fashion leading to the stereoisomer *E* depicted in Figure 2.

This configuration has important consequences in the crystal packing as it permits the existence of a vast network composed of strong and highly directional hydrogen bonding interactions (Figure 3a): (i) the carboxylic acid groups of two neighbouring units are engaged in a typical $R_2^2(8)$ graph set motif¹⁶ [O2–H2···O1ⁱ: $d_{D...A}$ of 2.933(2) Å with $\angle(\text{DAH})$ of *ca.* 165°; symmetry code (i) $-x, 2-y, -z$], which are reinforced by (ii) two very strong $S_1^1(6)$ intramolecular motifs [O3–H3···O1: $d_{D...A}$ of 2.470(2) Å with $\angle(\text{DAH})$ of *ca.* 151°]. The two aforementioned graph set motifs promote the existence of molecular dimers within the structure (Figure 3a) which are, in turn, interconnected by way of two N2–H2A···N1ⁱⁱ interactions [$d_{D...A}$ of 2.932(2) Å with $\angle(\text{DAH})$ of *ca.* 164°; symmetry code (i) $\frac{1}{2}-x, 2.5-y, 1-z$] involving the heterocyclic NH moiety and the pendant C≡N moiety. These interactions promote the existence of a third graph set motif, $R_2^2(16)$, which is in the genesis of the one-dimensional zigzag supramolecular tape depicted in Figure 3a. Individual tapes close pack in a typical alternate ABAB··· fashion along the [100] direction of the unit cell mediated by the need to effectively fill the available space (Figure 3b).





Figure 3. (a) Schematic representation of the one-dimensional zigzag supramolecular tape assembled by adjacent molecules of compound **6** engaged in strong and highly directional (N,O)–H···(N,O) hydrogen bonding interactions (dashed green lines – see main text for

geometrical details on the represented interactions). (b) Close packing of adjacent supramolecular tapes (represented in different colour) along the [100] direction of the unit cell depicting the actual crystal structure of compound **6**.

As anticipated, the treatment of compound **3a** with *p*-methoxyphenylhydrazine, in refluxing ethanol, in a basic medium, afforded as single product only pyrazole **7** (Scheme 1). The structure of the pyrazole **9** was excluded due to the absence of the typical signals of cyano groups in both the FT-IR and ^{13}C NMR spectra. The ^1H NMR of compound **7** showed all the expected signals which was not sufficient to differentiate between structures **7** and **8**. For this reason, we collected the HMQC and HMBC NMR spectra and performed an unambiguous assignment in the ^1H and ^{13}C NMR spectra (see experimental section). In the HMBC spectrum, no correlation peak between the pyrazole H-3 at 8.13 ppm and carbon signals at 130.67 (C-1'') was observed. This occurrence is characteristic only for structure **7** but not for **8**.¹⁷

Compound **3a** reacted with malononitrile in the presence of piperidine as a catalyst to give **10** in 75% yield. The structure of compound **10** was readily established from ^1H NMR data, which revealed all the expected protons of the indole moiety alongside with a singlet at 8.59 ppm for the H-4 of the pyridinone ring and a NH broad signal at 13.10 ppm. Two signals due to CN groups were found in the ^{13}C NMR spectrum at 115.44 and 116.96 ppm. The formation of the pyridine-3,5-dicarbonitrile **10** from the reaction of **3a** with malononitrile is assumed to take place through the sequence depicted in Scheme 2.




Scheme 2

Compound **3a** reacted with malononitrile in the presence of piperidine as a catalyst to give **10** in 75% yield. The structure of compound **10** was readily established from ^1H NMR data, which revealed all the expected protons of the indole moiety alongside with a singlet at 8.59 ppm for the H-4 of the pyridinone ring and a NH broad signal at 13.10 ppm. Two signals due to CN groups were found in the ^{13}C NMR spectrum at 115.44 and 116.96 ppm. The formation of the

pyridine-3,5-dicarbonitrile **10** from the reaction of **3a** with malononitrile is assumed to take place through the sequence depicted in Scheme 1.

The reactivity of the methylene group in compound **2** was exploited by reacting this compound with trichloroacetonitrile in ethanol in the presence of sodium acetate to obtain the new enamine **11** (Scheme 1). The structure of compound **11** was established by ^1H NMR data which revealed the absence of a signal for the methylene group and the emergence of another at 11.98 ppm corresponding to two protons of the amino group.

Recently Stanovnik *et al.* reported the synthesis of condensed indolylpyrimidones as meridianin analogs¹⁸ and polycyclic meridianin analogs with the uracil structural unit.¹⁹ Treatment of ethyl 2-cyano-3-(1H-indol-3-yl)acrylate (**13**) with guanidine hydrochloride in the presence of anhydrous potassium carbonate in ethanol at reflux temperature affords the corresponding 2-amino-6-(1H-indol-3-yl)-4-oxo-1,4-dihydropyrimidine-5-carbonitrile (**14**) (Scheme 3).



Scheme 3

Conclusion

Two novel indolyl enamionitriles (**3b** and **3c**) were prepared and reacted with guanidine hydrochloride yielding two new meridianine derivatives (**4b** and **4c**).

The reactivity of the enamionitrile **3a** was tested with *p*-methoxyphenylhydrazine and malononitrile giving a pyrazole derivative **7** and a pyridone derivative **10**, respectively.

The reaction of **3a** with hydroxylamine hydrochloride in basic medium produced, as expected, the oxazole derivative **5**. When the heating period was extended a different product, whose structure, **6**, was elucidated from single-crystal X-ray diffraction.

Experimental Section

General. Melting points were determined on a Gallenkamp melting point apparatus and uncorrected. FT-IR spectra were registered on a Perkin Elmer FT-IR 1600 using Nujol emulsions between NaCl plates. ^1H NMR (300 MHz) and ^{13}C NMR (75.4 MHz) spectra were recorded on a

Varian Unity Plus Spectrometer at 298 K or on a Bruker Avance III 400 spectrometer (400 MHz for ^1H and 100.6 MHz for ^{13}C). Chemical shifts are reported in ppm relative to solvent peak or TMS; coupling constants (J) are given in Hz. Double resonance, HMQC (heteronuclear multiple quantum coherence) and HMBC (heteronuclear multiple bond correlation) experiments were carried out for complete assignment of ^1H and ^{13}C signals in the NMR spectra. ESI mass spectrum was obtained on a LC-MS Finnigan LXQ spectrometer. High-resolution mass spectra were obtained on a Bruker FTMS APEXIII (ESI-TOF). Elemental analyses were obtained on a Leco CHNS-932 instrument.

General procedure for the preparation of compounds 2a-c

To a solution of cyanoacetic acid (5.0 g, 50 mmol) in Ac₂O (50 mL) at 50 °C, indole (5.85 g, 50 mmol) was added. The resulting solution was heated at 85 °C for 5 min. During that period 3-cyanoacetylindole started to crystallize. The mixture was allowed to cool and the solid was collected, washed with MeOH, and dried. The same procedure was applied with 2-methylindole to give **2b** and with 5-bromoindole to produce **2c**. Compounds **2a**, **b** were found to be identical to those described in the literature.¹⁴

3-(5-Bromo-1H-indol-3-yl)-3-oxopropanenitrile (2c). Pale yellow solid, Yield 85%, mp 296-298°C, FT-IR (Nujol; in cm^{-1}): $\nu = 3205$ (NH), 2252 (CN), 1634 (CO); ^1H NMR (DMSO- d_6): $\delta = 4.50$ (s, 2H, CH₂), 7.38 (dd, 1H, $J = 8.7, 1.8$ Hz, H-6), 7.49 (d, 1H, $J = 9.0$ Hz, H-7), 8.24 (d, 1H, $J = 2.1$ Hz, H-4), 8.41 (s, 1H, H-2), 12.35 (bs, 1H, NH). ^{13}C NMR (DMSO- d_6): $\delta = 29.48$ (CH₂), 113.87 (C-3), 114.57 (C-7), 115.07 (C-Br), 116.21 (CN), 123.11 (C-2), 125.94 (C-6), 126.88 (C-3a), 135.38 (C-7a), 136.55 (C-4), 183.10 (CO). Anal. Calcd. (in %) for C₁₁H₇BrN₂O (263.09): C, 50.22; H, 2.68; N, 10.65. Found: C, 50.10; H, 2.78; N, 10.65.

General procedure to prepare compounds 3a-c

A mixture of **2a-c** (10 mmol) and DMFDMA (11 mmol) was stirred for 5 min. at room temperature, and the yellow solid that formed was filtered off and crystallized from EtOH to afford **3a-c** in 78-88% yield. Compound **3a** was found to be identical to that previously described in the literature.⁵

3-(Dimethylamino)-2-(1H-indole-3-carbonyl)acrylonitrile (3a). Yellow crystals, yield 78%, mp 170-171°C (lit⁵. mp 160-163°C); $\delta = 3.26$ (s, 3H, CH₃), 3.35 (s, 3H, CH₃), 7.13 (td, 1H, $J = 1.2, 6.9$ Hz, H-5), 7.18 (td, 1H, $J = 6.9$ Hz, H-6), 7.46 (dd, 1H, $J = 7.8, 2.1$ Hz, H-7), 7.99 (s, 1H, =CH), 8.13 (dd, 1H, $J = 7.5, 2.1$ Hz, H-4), 8.27 (d, 1H, $J = 3$ Hz, H-2), 11.75 (s, 1H, NH). ^{13}C NMR (DMSO- d_6): $\delta = 38.51$ (CH₃), 47.39 (CH₃), 77.62 (C-CN), 111.70 (C-7), 114.70 (C-3), 121.12 (C-5), 121.75 (C-4 or CN), 121.78 (C-4 or CN), 122.49 (C-6), 126.77 (C-3a), 131.14 (C-2), 135.83 (C-7a), 158.67 (=CH), 181.74 (CO).

3-(Dimethylamino)-2-(2-methyl-1H-indole-3-carbonyl)acrylonitrile (3b). Yellow crystals, yield 85%, mp 192-193°C, FT-IR (Nujol; in cm^{-1}): $\nu = 3274$ (NH), 2225 (CN), 1689 (CO); ^1H NMR (DMSO- d_6): $\delta = 2.48$ (s, 3H, CH₃), 3.19 (s, 3H, N-CH₃), 3.35 (s, 3H, N-CH₃), 7.00-7.11 (m, 2H, H-5, 6), 7.32 (dd, 1H, $J = 6.9, 2.1$ Hz, H-7), 7.56 (dd, 1H, $J = 6.9, 2.1$ Hz, H-4), 7.74 (s,

1H, =CH), 11.54 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 13.51 (CH₃), 38.44 and 47.09 (2 x N-CH₃), 81.38 (C-CN), 110.88 (C-7), 112.90 (C-2), 119.68 (C-4), 120.03 (CN and C-5 or C6), 121.19 (C-5 or C-6), 126.91 (C-3a), 134.77 (C-7a), 139.69 (C-3), 158.53 (=CH), 185.49 (CO). Anal. Calcd. (in %) for C₁₅H₁₅N₃O (253.30); C, 71.13; H, 5.97; N, 16.59. Found: C, 70.93; H, 6.00; N, 16.66.

2-(5-Bromo-1H-indole-3-carbonyl)-3-(dimethylamino)acrylonitrile (3c). Yellow crystals, Yield 88%, mp 252-254°C, FT-IR (Nujol; in cm⁻¹): ν = 3285 (NH), 2227 (CN), 1664 (CO); ¹H NMR (DMSO-*d*₆): δ = 3.27 (s, 3H, CH₃), 3.31 (s, 3H, CH₃), 7.30 (dd, 1H, *J* = 8.7, 1.8 Hz, H-6), 7.45 (d, 1H, *J* = 9.0 Hz, H-7), 7.99 (s, 1H, =CH), 8.28 (d, 1H, *J* = 1.8 Hz, H-4), 8.32 (s, 1H, H-2), 11.92 (bs, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 47.49 and 38.57 (2 x CH₃), 77.36 (C-CN), 113.94 (C-3 or C-5), 114.02 (C-5 or C-3), 114.22 (C-7), 121.64 (CN), 123.95 (C-4), 125.06 (C-6), 128.59 (C-3a), 132.33 (C-2), 134.57 (C-7a), 158.75 (C-2), 181.42 (CO). Anal. Calcd. (in %) for C₁₄H₁₂BrN₃O (318.17): C, 52.85; H, 3.80; N, 13.21. Found: C, 52.86; H, 3.98; N, 13.21.

General procedure to prepare meridianin derivatives 4a-c

A mixture of enamionitrile **3a-c** (10 mmol), guanidine hydrochloride (12.0 mmol), anhydrous K₂CO₃ (2.0 g, 15.0 mmol), and absolute ethanol (20 mL) was heated at reflux for 7 h. After cooling, the mixture was poured into ice-water and the solid formed was filtered off to afford 5'-cyano-meridianin derivatives **4a-c** as yellow solids. Recrystallization from EtOH led to overall yields of 70-78%. Spectral data for compound **4a** are in good agreement with those reported in the literature.⁵

2-Amino-4-(1H-indol-3-yl)pyrimidine-5-carbonitrile (4a). Off white solid powder (70%), mp 257-258°C (lit.⁵ mp 258-259°C). ¹H NMR (DMSO-*d*₆): δ = 7.12-7.27 (m, 2H, H-5', 6'), 7.50 (d, 1H, *J* = 7.5 Hz, H-7'), 7.54 and 7.64 (2 bs, 2H, NH₂), 8.47 (s, 1H, H-6), 8.57 (s, 1H, H-2'), 8.65 (d, 1H, *J* = 7.2 Hz, H-4'), 11.95 (bs, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 89.23 (C-5), 111.56 (C-3'), 112.04 (C-7'), 119.82 (CN), 121.09 (C-5'), 122.80 (C-6'), 123.27 (C-4'), 125.73 (C-3'a), 130.04 (C-2'), 136.36 (C-7'a), 163.14 (C-4 or C-2), 163.17 (C-2 or C-4), 165.35 (C-6).

2-Amino-4-(2-methyl-1H-indol-3-yl)pyrimidine-5-carbonitrile (4b). Yellow powder (74%), mp 280-282°C, FT-IR (Nujol; in cm⁻¹): ν = 3295 (NH), 3150 (NH₂), 2215 (CN); ¹H NMR (DMSO-*d*₆): δ = 2.51 (s, 3H, CH₃), 7.02-7.14 (m, 2H, H-5', 6'), 7.34-7.36 (m, 1H, H-7'), 7.59-7.61 (m, 1H, H-4'), 7.64 (s, 2H, NH₂), 8.65 (s, 1H, H-6), 11.64 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 13.82 (CH₃), 94.40 (C-5), 109.72 (C-3'), 110.94 (C-7'), 118.40 (CN), 119.51 (C-4'), 119.78 (C-5'), 121.47 (C-6'), 126.35 (C-3'a), 135.15 (C-7'a), 137.95 (C-2'), 163.17 (C-4 or C-2), 163.28 (C-2 or C-4), 165.37 (C-6). Anal. Calcd. (in %) for C₁₄H₁₁N₅ (249.27): C, 67.46; H, 4.45; N, 28.10. Found: C, 67.38; H, 4.52; N, 28.15.

2-Amino-4-(5-bromo-1H-indol-3-yl)pyrimidine-5-carbonitrile (4c). Yellow crystals (78%), mp 325-327°C, FT-IR (Nujol; in cm⁻¹): ν = 3428 (NH), 3290, 3148 (NH₂), 2211 (CN); ¹H NMR (DMSO-*d*₆): δ = 7.34-7.36 (m, 1H, H-6'), 7.47-7.49 (m, 1H, H-7'), 7.57, 7.81 (bs, 2H, NH₂), 8.49 (s, 1H, H-2'), 8.57 (s, 1H, H-6), 8.75 (d, 1H, H-4'), 12.10 (bs, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 89.31 (C-5), 111.12 (C-3'), 114.06 (CN), 114.15 (C-7'), 119.60 (C-5'), 125.01 (C-4'),

125.51 (C-6'), 127.30 (C-3'a), 131.18 (C-2'), 135.12 (C-7'a), 162.74 (C-4 or C-2), 163.11 (C-2 or C-4), 163.41 (C-6). Anal. Calcd. (in %) for C₁₃H₈BrN₅ (314.14): C, 49.70; H, 2.57; N, 22.29. Found: C, 49.35; H, 2.68; N, 22.10.

(5-Amino-isoxazol-4-yl)-(1H-indol-3-yl)-methanone (5). A mixture of enaminonitrile **3a** (100.5 mg, 0.42 mmol) and anhydrous K₂CO₃ (84 mg, 0.61 mmol) in absolute ethanol (20 mL) was stirred for 10 min. at room temperature. Hydroxylamine hydrochloride (0.5 mmol) was added and the mixture was warmed at 60° for 30 min, cooled, poured into ice-water, and extracted with diethyl ether (3x50 mL). The combined extracts were dried (MgSO₄) and the solvent was evaporated to give compound **5** as an off-white solid (25 mg, 29%) mp 217.0-219.5°C; ¹H NMR (DMSO-*d*₆): 7.10-7.24 (m, 2H, H-5' and 6'), 7.46 (d, J=7.0 Hz, 1H, H-7'), 8.16-8.20 (s, 2H, NH₂, exchangeable with D₂O), 8.24 (d, 1H, J = 7.0 Hz, H-4'), 8.31(1H, d, J=3Hz, H-2'), 8.97 (1H, s, H-3), 11.95 (bs, 1H, NH, exchangeable with D₂O). ¹³C NMR (DMSO-*d*₆): δ = 94.30 (C-4), 115.38 (C-3'), 111.99 (C-7'), 121.32 (C-5'), 121.54 (C-4'), 122.70 (C-6'), 126.28 (C-3'a), 131.40 (C-2'), 136.26 (C-7'a), 149.82 (C-3), 171.49 (C-5), 180.89 (CO). ESI-TOF, C₁₂H₁₀N₃O₂ (M⁺+1) Calc: 228.07675; Found: 228.07675.

General procedure to prepare compounds **6** and **7**.

A mixture of enaminonitrile **3a** (10 mmol), hydroxylamine hydrochloride (**6**) or *p*-methoxyphenyl hydrazine hydrochloride (**7**) (12.0 mmol), anhydrous K₂CO₃ (2.0 g, 15.0 mmol), and absolute ethanol (20 mL) was heated at reflux for 7 h. After cooling, the mixture was poured into ice-water and the resulting solid was filtered off and recrystallized from EtOH.

2-Cyano-3-hydroxy-3-(1H-indol-3-yl)-acrylic acid (6). Brown crystals (81%), mp 235-237°C, FT-IR (Nujol): ν = 3399, 3256 (NH), 2208 (CN), 1641 (CO) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ = 7.19 (dt, 1H, H-5'), 7.24 (dt, 1H, J= 7.2 and 1.2 Hz, H-6'), 7.53 (d, 1H, J = 7.5Hz, H-7'), 7.60-8.40 (br s, 1H, OH, D₂O exchangeable), 8.10 (d, 1H, J = 7.5 Hz, H-4'), 8.48 (d, 1H, J = 3.2 Hz, H-2'), 12.20 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO-*d*₆): δ = 69.53 (C-2), 109.30 (C-3'), 112.55 (C-7'), 119.19 (CN), 121.91 (C-5') 121.96 (C-4'), 123.10 (C-6'), 125.59 (C-3'a), 132.28 (C-2'), 135.98 (C-7'a), 173.96 (C-1), 181.55 (C-3). ESI-MS: 208.17 ([M-1]⁺). Anal. Calcd. (in %) for C₁₂H₇N₃O (209.20): C, 68.89; H, 3.37; N, 20.09. Found: C, 68.45; H, 3.27; N, 20.39.

(5-Amino-1-(4-methoxyphenyl)-1H-pyrazol-4-yl)(1H-indol-3-yl)methanone (7). Brown crystals (81%), mp 230-232°C, FT-IR (Nujol): ν = 3278 (NH), 1650 (CO), cm⁻¹; ¹H NMR (DMSO-*d*₆): δ = 3.82 (s, 3H, OCH₃), 6.81 (s, 2H, NH₂), 7.10 (d, 2H, J = 9.0 Hz, (H-3'',5')), 7.14-7.22 (m, 2H, H-5', 6'), 7.45-7.47 (m, 1H, H-7'), 7.49 (d, 2H, J = 9.0 Hz, (H-2'',6'')), 8.13 (s, 1H, H-3), 8.23-8.25 (m, 1H, H-4'), 8.29 (d, 1H, J = 2.7 Hz, H-2'), 11.86 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆): δ = 55.47 (OCH₃), 104.09 (C-4), 111.88 (C-7'), 114.58 (C-3'',5'), 115.97 (C-3'), 121.05 (C-5'), 121.56 (C-4'), 122.51 (C-6'), 125.52 (C-2'',6''), 126.40 (C-3'a), 130.67 (C-1'), 131.03 (C-2'), 136.22 (C-7'a), 139.96 (C-3), 150.40 (C-5), 158.47 (C-4'), 182.94 (CO). ESI⁺-MS: 333.33 ([M+1]⁺). Anal. Calcd. (in %) for C₁₉H₁₆N₄O₂ (332.36): C, 68.66; H, 4.85; N, 16.86. Found: C, 68.49; H, 5.00; N, 16.86.

6-(1*H*-Indol-3-yl)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitrile (10). To a mixture of enaminonitrile **3a** (10 mmol) and malononitrile (0.66 g; 10 mmol) in ethanol (15 mL) piperidine (0.2 mL) was added. The reaction mixture was refluxed for 3 h and was then left to cool to room temperature. The precipitated product was collected by filtration and crystallized from ethanol to afford **10** as brown crystals in 75 % yield. mp 198-200°C, FT-IR (Nujol): $\nu = 3266$ (NH), 22211 (CN), 1634 (CO), cm^{-1} ; ^1H NMR (DMSO- d_6): $\delta = 7.18$ -7.29 (m, 2H, H-5', 6'), 7.52-7.55 (m, 1H, H-7'), 7.72 (d, 1H, $J = 7.2$ Hz, H-4'), 8.14 (d, 1H, $J = 3.0$ Hz, H-2'), 8.59 (s, 1H, H-4), 12.24 (s, 1H, NH indole), 13.10 (bs, 1H, NH). ^{13}C NMR (DMSO- d_6): $\delta = 88.71$ (C-5), 99.55 (C-3), 106.14 (C-3'), 122.58 (C-7'), 115.44 (CN), 116.96 (CN), 120.46 (C-4'), 121.0 (C-5'), 122.97 (C-6'), 124.16 (C-3'a), 131.11 (C-2'), 136.31 (C-7'a), 150.53 (C-4), 155.05 (C-6), 160.17 (CO). ESI-MS: 259.10 ($[\text{M}-1]^+$). Anal. Calcd. (in %) for $\text{C}_{15}\text{H}_8\text{N}_4\text{O}$ (260.25): C, 69.23; H, 3.10; N, 21.53. Found: C, 69.09; H, 3.41; N, 21.68.

3-Amino-4,4,4-trichloro-2-(1*H*-indole-3-carbonyl)but-2-enenitrile (11). To a solution of **2a** (10 mmol) in ethanol (25 ml) and sodium acetate (4.1 g, 50 mmol), trichloroacetonitrile (4.33 g, 30 mmol) was added. The reaction mixture was stirred for 48h and then poured into water, and the solid product was filtered off and crystallized from dimethylformamide to give **9** as a brown powder (74%), mp 212-214°C, FT-IR (Nujol): $\nu = 3279$ (NH), 2215 (CN), 1620 (CO), cm^{-1} ; ^1H NMR (DMSO- d_6): $\delta = 7.18$ -7.24 (m, 2H, H-5', 6'), 7.48-7.51 (m, 1H, H-7'), 8.16-8.18 (m, 1H, H-4'), 8.47 (d, 1H, $J = 3.2$ Hz, H-2'), 9.42 (bs, 1H, NH), 11.98 (s, 2H, NH_2). ^{13}C NMR (DMSO- d_6): $\delta = 76.10$ (C-2) 91.61 (C-4, CCl_3), 112.22 (C-7'), 114.52 (C-3'), 119.80 (CN), 121.76 (C-5'), 121.78 (C-4'), 122.92 (C-6'), 126.54 (C-3'a), 132.28 (C-2'), 135.77 (C-7'a), 167.41 (C-3), 185.45 (CO). ESI-MS: 326.17 (^{35}Cl , $[\text{M}-1]^+$), 328.08 (^{35}Cl (2), ^{37}Cl , $[\text{M}-1]^+$), 330.00 (^{35}Cl , ^{37}Cl (2) $[\text{M}-1]^+$). Anal. Calcd. (in %) for $\text{C}_{13}\text{H}_8\text{Cl}_3\text{N}_3\text{O}$ (328.58): C, 47.52; H, 2.45; N, 12.79. Found: C, 47.26; H, 2.85; N, 12.81.

Ethyl 2-cyano-3-(1*H*-indol-3-yl)acrylate (13). To a solution of 3-formylindole (10 mmol) in ethanol (25 ml) and ethylcyanoacetate (10 mmol), and piperidine (0.2 mL) was added. The reaction mixture was refluxed for 2 h and then left to cool to room temperature. The solid that precipitated was filtered off and recrystallized from ethanol to give **13** as yellow crystals in 92% yield. mp 170-171°C, FT-IR (Nujol): $\nu = 3278$ (NH), 2224 (CN), 1680 (CO), cm^{-1} ; ^1H NMR (CDCl_3): $\delta = 1.41$ (t, 3H, $J = 7.2$ Hz, CH_3), 4.38 (q, 2H, $J = 7.2$ Hz, CH_2), 7.32-7.36 (m, 2H, H-5',6'), 7.48-7.51 (m, 1H, H-7'), 7.84-7.86 (m, 1H, H-4'), 8.64 (s, 1H, =CH), 8.67 (d, 1H, $J = 3.3$ Hz, H-2'), 9.24 (bs, 1H, NH). ^{13}C NMR (CDCl_3): $\delta = 14.30$ (CH_3), 62.04 (CH_2), 94.93 (C-2), 111.23 (C-3'), 112.20 (C-7'), 118.13 (CN), 118.33 (C-4'), 122.65 (C-5'), 124.23 (C-6'), 127.39 (C-3'a), 130.68 (C-2'), 135.60 (C-7'a), 146.55 (C-3'), 163.76 (C-1). Anal. Calcd. (in %) for $\text{C}_{14}\text{H}_{12}\text{N}_2\text{O}_2$ (240.26): C, 69.99; H, 5.03; N, 11.66. Found: C, 69.97; H, 5.16; N, 11.86.

2-Amino-6-(1*H*-indol-3-yl)-4-oxo-1,4-dihydropyrimidine-5-carbonitrile (14). A mixture of **13** (10 mmol), guanidine hydrochloride (12.0 mmol), anhydrous K_2CO_3 (2.0 g, 15.0 mmol), and absolute ethanol (20 mL) was heated at reflux temperature for 7 h. After cooling, the mixture was poured into ice-water and neutralized with acetic acid. A solid product formed which was filtered off and recrystallized from EtOH to afford **14** as a yellow solid in 77 % yield. mp 252-

253°C, FT-IR (Nujol): $\nu = 3327$ (NH), 2211 (CN), 1659 (CO), cm^{-1} ; ^1H NMR (DMSO- d_6): $\delta = 7.10$ - 7.22 (m, 4H, H-5', 6', NH₂), 7.47 (d, 1H, $J = 8.4$ Hz, H-7'), 8.44 (d, 1H, $J = 3.0$ Hz, H-2'), 8.57 (d, 1H, $J = 7.5$ Hz, H-4'), 11.31 (s, 1H, NH indole), 11.92 (s, 1H, NH). ^{13}C NMR (DMSO- d_6): $\delta = 79.40$ (C-5) 111.77 (C-3'), 111.96 (C-7'), 119.28 (CN), 120.88 (C-5'), 122.54 (C-6'), 123.51 (C-4'), 126.13 (C-3'a), 130.51 (C-2'), 136.25 (C-7'a), 155.98 (C-2), 162.21 (CO), 166.67 (C-6). ESI-MS: 250.08 ([M-1]⁺). Anal. Calcd. (in %) for C₁₃H₉N₅O (251.24): C, 62.15; H, 3.61; N, 27.87. Found: C, 62.40; H, 3.26; N, 27.77.

Single-crystal X-ray Diffraction

A single-crystal of compound **6** was manually harvested from the crystallization vial and mounted on a Hampton Research CryoLoop using FOMBLIN Y perfluoropolyether vacuum oil (LVAC 25/6) purchased from Aldrich²⁰ with the help of a Stemi 2000 stereomicroscope equipped with Carl Zeiss lenses. Data were collected at 150(2) K on a Bruker X8 Kappa APEX II charge-coupled device (CCD) area-detector diffractometer (Mo K $_{\alpha}$ graphite-monochromated radiation, $\lambda = 0.71073$ Å) controlled by the APEX2 software package,²¹ and equipped with an Oxford Cryosystems Series 700 cryostream monitored remotely using the software interface Cryopad.²² Images were processed using the software package SAINT+,²³ and data were corrected for absorption by the multi-scan semi-empirical method implemented in SADABS.²⁴ The crystal structure was solved by employing the direct methods implemented in SHELXS-97.^{25,26} This strategy allowed the immediate location of the vast majority of the atoms. All the remaining non-hydrogen atoms were directly located from difference Fourier maps calculated from successive full-matrix least squares refinement cycles on F^2 using SHELXL-97.^{26,27} All non-hydrogen atoms have been successfully refined using anisotropic displacement parameters.

Hydrogen atoms bound to carbon/nitrogen and oxygen were placed at their idealized positions using the *HFIX 43* or *I47* instructions in SHELXL and included in subsequent refinement cycles in riding-motion approximation with isotropic thermal displacement parameters (U_{iso}) fixed at 1.2 or 1.5 $\times U_{\text{eq}}$ of the carbon/nitrogen or oxygen atom to which they are attached, respectively. The last difference Fourier map synthesis showed the highest peak (0.494 eÅ⁻³) and deepest hole (-0.635 eÅ⁻³) located at 0.40 Å and 0.51 Å from O1 and O2, respectively.

Crystal data: C₁₂H₈N₂O₃, $M = 228.20$, monoclinic, space group $C2/c$, $Z = 8$, $a = 27.964(6)$ Å, $b = 5.3241(11)$ Å, $c = 17.278(4)$ Å, $\beta = 124.186(19)^\circ$, $V = 2127.9(8)$ Å³, $\mu(\text{MoK}_{\alpha}) = 0.105$ mm⁻¹, $D_c = 1.425$ g cm⁻³, brown prism with crystal size of ca. 0.25 \times 0.20 \times 0.20 mm³. Of a total of 39590 reflections collected, 2856 were independent ($R_{\text{int}} = 0.0308$). Final $R1 = 0.0602$ [$I > 2\sigma(I)$] and $wR2 = 0.2172$ (all data). Data completeness to $\theta = 29.13^\circ$, 99.6%.

Crystallographic data (excluding structure factors) for compound **6** have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-816317. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 2EZ, U.K. Fax: (+44) 1223 336033. E-mail: deposit@ccdc.cam.ac.uk.

Acknowledgements

We are grateful to Fundação para a Ciência e a Tecnologia and FEDER (POCTI-SFA-3-686, for general financial support; REEQ/ 630/QUI/2005, for LCMS; and specific funding for the purchase of the single-crystal diffractometer). We also acknowledge FCT for funds to support the NMR spectrometers as part of the National NMR Network (RNRMN). Thanks are due also for the post-doctoral research grant to A. Salaheldin (SFRH/BPD/31490/2006). We further thank Miss Elisa Pinto for obtaining the NMR and elemental analyses data, and Miss Natércia Nunes for LCMS determinations.

References

1. Salaheldin, A. M.; Alphy, M. K. *J. Heterocycl. Chem.* **2008**, *45*, 307.
2. Franco, L. H.; Joffe, E. B. K.; Puricelly, L.; Tatian, M.; Seldes, A. M.; Palermo, J. A. *J. Nat. Prod.* **1998**, *61*, 1130.
3. Franco, L. H.; Palermo, J. A. *Chem. Pharm. Bull.* **2003**, *51*, 975.
4. Gompel, M.; Leost, M.; Bal de Kier Joffe, E.; Puricelli, L.; Franco, L. H.; Palermo, J.; Meijer, L. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1703.
5. Radwan, M. A. A.; El-Sherbiny, M. *Bioorg. Med. Chem.* **2007**, *15*, 1206.
6. Jiang, B.; Yang, C.-G. *Heterocycles* **2000**, *53*, 1489.
7. Bredereck, H.; Effenberger, F.; Botsch, H.; Rehn, H. *Chem. Ber.* **1965**, *98*, 1081.
8. Fresneda, P. M.; Molina, P.; Bleda, J. A. *Tetrahedron* **2001**, *57*, 2355.
9. Karpov, A. S.; Merkul, E.; Rominger, F.; Müller, T. J. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 6951.
10. Salaheldin, A. M.; Oliveira-Campos, A. M. F.; Rodrigues, L. M. *Tetrahedron Lett.* **2007**, *48*, 8819.
11. Oliveira-Campos, A. M. F.; Salaheldin, A. M.; Rodrigues, L. M. *Arkivoc* **2007**, *xvi*, 92.
12. Salaheldin, A. M.; Oliveira-Campos, A. M. F.; Rodrigues, L. M. *Arkivoc* **2008**, *xiv*, 180.
13. Salaheldin, A. M.; Oliveira-Campos, A. M. F.; Rodrigues, L. M. *Synth. Commun.* **2009**, *39*, 1186.
14. Slatt, J.; Romero, I.; Bergman, J. *Synthesis* **2004**, 2760.
15. US Patent 6579983, Celltech R & D Ltd. **2000**; *Chem. Abstr.*, **134**, 71598, **2000**.
16. Bernstein, J.; Davis, R. E.; Shimoni, L.; Chang, N. L., *Angew. Chem. Int. Edit. Engl.* **1995**, *34*, 1555-1573.
17. Radwan, M. A. A.; Ragab, E. A.; Shaaban, M. R.; El-Nezhawy, A. O. H. *Arkivoc* **2009**, *vii*, 281.
18. Jakše, R.; Svete, J.; Stanovnik, B.; Golobic, A. *Tetrahedron* **2004**, *60*, 4601.
19. Časar, Z.; Bevk, D.; Svete, J.; Stanovnik, B. *Tetrahedron* **2005**, *61*, 7508.
20. Kottke, T.; Stalke, D. *J. Appl. Cryst.* **1993**, *26*, 615-619.

21. APEX2, *Data Collection Software Version 2.1-RC13*, Bruker AXS, Delft, The Netherlands **2006**.
22. Cryopad, *Remote monitoring and control, Version 1.451*, Oxford Cryosystems, Oxford, United Kingdom **2006**.
23. SAINT+, *Data Integration Engine v. 7.23a* © **1997-2005**, Bruker AXS, Madison, Wisconsin, USA.
24. Sheldrick, G. M., *SADABS v.2.01*, Bruker/Siemens Area Detector Absorption Correction Program **1998**, Bruker AXS, Madison, Wisconsin, USA.
25. Sheldrick, G. M., *SHELXS-97, Program for Crystal Structure Solution*, University of Göttingen **1997**.
26. Sheldrick, G. M. *Acta Cryst. A* **2008**, *64*, 112-122.
27. Sheldrick, G. M., *SHELXL-97, Program for Crystal Structure Refinement*, University of Göttingen **1997**.